Mirae Asset Global Investments Co. Ltd. Sells 34,789 Shares of Qiagen (NYSE:QGEN)

Mirae Asset Global Investments Co. Ltd. lessened its holdings in shares of Qiagen (NYSE:QGENGet Rating) by 13.5% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 223,590 shares of the company’s stock after selling 34,789 shares during the period. Mirae Asset Global Investments Co. Ltd. owned about 0.10% of Qiagen worth $10,956,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Neuberger Berman Group LLC grew its position in shares of Qiagen by 35.5% during the 1st quarter. Neuberger Berman Group LLC now owns 2,429,455 shares of the company’s stock worth $119,135,000 after purchasing an additional 637,137 shares in the last quarter. Toroso Investments LLC grew its position in shares of Qiagen by 11.0% during the 1st quarter. Toroso Investments LLC now owns 7,392 shares of the company’s stock worth $362,000 after purchasing an additional 735 shares in the last quarter. Weiss Multi Strategy Advisers LLC acquired a new position in shares of Qiagen during the 1st quarter worth approximately $1,008,000. Mirabella Financial Services LLP acquired a new position in shares of Qiagen during the 1st quarter worth approximately $1,685,000. Finally, KB Financial Partners LLC grew its position in shares of Qiagen by 21.3% during the 1st quarter. KB Financial Partners LLC now owns 4,999 shares of the company’s stock worth $245,000 after purchasing an additional 877 shares in the last quarter. Institutional investors and hedge funds own 55.65% of the company’s stock.

Qiagen Stock Performance

NYSE QGEN opened at $43.35 on Wednesday. The company has a current ratio of 2.23, a quick ratio of 1.89 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $9.84 billion, a price-to-earnings ratio of 19.53, a P/E/G ratio of 1.27 and a beta of 0.33. The firm’s 50 day simple moving average is $47.71 and its 200 day simple moving average is $46.85. Qiagen has a 1 year low of $41.32 and a 1 year high of $58.00.

Qiagen (NYSE:QGENGet Rating) last posted its quarterly earnings results on Tuesday, July 26th. The company reported $0.51 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.06. The business had revenue of $515.51 million for the quarter, compared to analyst estimates of $498.09 million. Qiagen had a net margin of 22.75% and a return on equity of 19.26%. As a group, research analysts expect that Qiagen will post 2.21 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, StockNews.com lowered shares of Qiagen from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 29th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $54.50.

Qiagen Company Profile

(Get Rating)

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.

Further Reading

Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen (NYSE:QGENGet Rating).

Institutional Ownership by Quarter for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.